Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

rhenium Re 186 etidronate

An synthetic compound containing the organic phosphonate hydroxyethylidene diphosphonate (HEDP) labeled with the radioisotope rhenium Re 186. Re-186 etidronate binds to hydroxyapatite in bone, delivering a cytotoxic dose of beta radiation to primary and metastatic bone tumors. Re-186 is a beta emitter with a short half-life, a radioisotope profile that provides localized antitumor radiocytotoxicity while sparing extramedullary bone marrow tissues.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:186Re-etidronate
Re 186 hydroxyethylidene diphosphonate
Re-186 hydroxyethylidene diphosphonate
rhenium Re-186 hydroxyethylidene diphosphonate
rhenium-186 HEDP
Abbreviation:Re-186 HEDP
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search